MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
MiNK Therapeutics (NASDAQ: INKT) has announced an upcoming presentation at the ASCO GI Symposium in San Francisco from January 23-25, 2025. The presentation will focus on their ongoing Phase 2 study of agenT-797, an invariant natural killer T (iNKT) cell therapy, combined with Agenus' botensilimab/balstilimab for treating refractory gastric cancer.
The abstract (TPS515), titled 'A phase II study of agenT-797, botensilimab, and balstilimab in patients with advanced, refractory gastroesophageal adenocarcinoma,' will be presented by Dr. Samuel Cytryn during the Trials in Progress Poster Session on January 23, 2025. Complete abstracts will be released on January 21st, 2025, at 5:00 PM ET, with presentation materials later available on MiNK's website.
MiNK Therapeutics (NASDAQ: INKT) ha annunciato una prossima presentazione al Simposio ASCO GI a San Francisco dal 23 al 25 gennaio 2025. La presentazione si concentrerà sul loro ongoing studio di fase 2 di agenT-797, una terapia con cellule T natural killer invarianti (iNKT), combinata con il botensilimab/balstilimab di Agenus per il trattamento del cancro gastrico refrattario.
L'abstract (TPS515), intitolato 'Uno studio di fase II su agenT-797, botensilimab e balstilimab in pazienti con adenocarcinoma gastroesofageo avanzato e refrattario,' sarà presentato dal Dr. Samuel Cytryn durante la Sessione Poster dei Trials in Progress il 23 gennaio 2025. Gli abstract completi saranno rilasciati il 21 gennaio 2025 alle 17:00 ET, con i materiali della presentazione successivamente disponibili sul sito web di MiNK.
MiNK Therapeutics (NASDAQ: INKT) ha anunciado una próxima presentación en el Simposio ASCO GI en San Francisco del 23 al 25 de enero de 2025. La presentación se centrará en su estudio de fase 2 en curso de agenT-797, una terapia con células T natural killer invariantes (iNKT), combinada con el botensilimab/balstilimab de Agenus para tratar el cáncer gástrico refractario.
El resumen (TPS515), titulado 'Un estudio de fase II de agenT-797, botensilimab y balstilimab en pacientes con adenocarcinoma gastroesofágico avanzado y refractario,' será presentado por el Dr. Samuel Cytryn durante la Sesión de Pósters de Ensayos en Progreso el 23 de enero de 2025. Los resúmenes completos se publicarán el 21 de enero de 2025 a las 5:00 PM ET, y los materiales de la presentación estarán disponibles posteriormente en el sitio web de MiNK.
MiNK Therapeutics (NASDAQ: INKT)는 2025년 1월 23일부터 25일까지 샌프란시스코에서 열리는 ASCO GI 심포지엄에서 발표할 예정이라고 발표했습니다. 이 발표는 불응성 위암 치료를 위한 Agenus의 botensilimab/balstilimab와 결합한 불변 자연 살해 T 세포(iNKT) 치료제인 agenT-797의 2상 연구에 초점을 맞춥니다.
'불응성 및 진행성 위식도 선암 환자에서의 agenT-797, botensilimab, balstilimab에 대한 2상 연구'라는 제목의 초록(TPS515)은 2025년 1월 23일 Trials in Progress 포스터 세션에서 Samuel Cytryn 박사에 의해 발표될 예정입니다. 전체 초록은 2025년 1월 21일 오후 5:00 ET에 공개되며, 발표 자료는 이후 MiNK의 웹사이트에서 확인할 수 있습니다.
MiNK Therapeutics (NASDAQ: INKT) a annoncé une prochaine présentation lors du Symposium ASCO GI à San Francisco du 23 au 25 janvier 2025. La présentation se concentrera sur leur étude de phase 2 en cours d'agenT-797, une thérapie par cellules T naturelles tueuses invariantes (iNKT), combinée avec le botensilimab/balstilimab d'Agenus pour traiter le cancer gastrique réfractaire.
L'abstract (TPS515), intitulé 'Une étude de phase II de l'agenT-797, du botensilimab et du balstilimab chez des patients atteints d'adénocarcinome gastro-œsophagien avancé et réfractaire,' sera présenté par Dr. Samuel Cytryn lors de la session d'affiches Trials in Progress le 23 janvier 2025. Les résumés complets seront publiés le 21 janvier 2025 à 17h00 ET, et les documents de présentation seront ensuite disponibles sur le site web de MiNK.
MiNK Therapeutics (NASDAQ: INKT) hat eine bevorstehende Präsentation beim ASCO GI Symposium in San Francisco vom 23. bis 25. Januar 2025 angekündigt. Die Präsentation wird sich auf ihre laufende Phase 2 Studie zu agenT-797, einer invariant natürlichen Killer-T-Zelltherapie (iNKT), konzentrieren, die mit den Arzneimitteln botensilimab/balstilimab von Agenus zur Behandlung von refraktärem Magenkrebs kombiniert wird.
Das Abstract (TPS515) mit dem Titel 'Eine Phase-II-Studie zu agenT-797, botensilimab und balstilimab bei Patienten mit fortgeschrittenem refraktärem gastroösophagealem Adenokarzinom' wird von Dr. Samuel Cytryn während der Trials in Progress Poster-Session am 23. Januar 2025 präsentiert. Die vollständigen Abstracts werden am 21. Januar 2025 um 17:00 Uhr ET veröffentlicht, die Präsentationsmaterialien sind später auf der Website von MiNK verfügbar.
- None.
- None.
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium that will take place on January 23-25, 2025, in San Francisco, California. The poster presentation will highlight the ongoing Phase 2 study of agenT-797 in combination with Agenus’ botensilimab/balstilimab in patients with refractory gastric cancer.
Presentation Details
Abstract Title: A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
Abstract Number: TPS515
Presenting Author: Dr. Samuel Cytryn
Session: Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Session Date and Time: 1/23/2025, 11:30 AM-1:00 PM
Complete abstracts will be released at 5:00 PM ET on January 21st, 2025. Data presented at the conference will be available to view in the publications section of the MiNK website (https://minktherapeutics.com/publications/) following the ASCO GI Meeting.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
What is MiNK Therapeutics (INKT) presenting at ASCO GI 2025?
When and where will INKT's ASCO GI 2025 presentation take place?
What is the abstract number and title for INKT's ASCO GI presentation?
When will INKT's complete ASCO GI abstract be available?
What type of therapy is INKT's agenT-797?
